



ASX RELEASE
25 February 2013

Section 708A(5)(e) disclosure notice – Issue of shares by Tissue Therapies Limited (Issuer) (ASX Code: TIS)

The Company relies upon case 1 in section 708A(5) *Corporations Act 2001* (Cth) (**Corporations Act**) in respect of the placement of shares to sophisticated and institutional investors as set out in the Appendix 3B dated 25 February 2013. As required by section 708A(6) *Corporations Act*, the Issuer named above notifies ASX, the operator of the prescribed financial market, of details about the issue of securities by placement to persons in response to offers made by Company under section 708A(5) *Corporations Act*, in this notice.

Details of the securities issued

Class of securities:	Fully paid ordinary shares
ASX Code of the securities:	TIS
Date of the issue or expected issue of the securities:	25 February 2013
Total number of securities issued or expected to be issued:	41,512,297

Signed for the Issuer:

Date: 25 February 2013 Name: Drummond McKenzie Position held: Company Secretary

Signature:

- 1 The above securities will be, or have been, issued without disclosure to investors under Part 6D.2 *Corporations Act*.
- 2 This notice is given under section 708A(5)(e) and in accordance with section 708A(6) *Corporations Act*.
- 3 At the date of this notice, the Issuer has complied with the provisions of Chapter 2M *Corporations Act* in application to the Issuer and the Issuer has complied with section 674 *Corporations Act*.
- 4 There is no 'excluded information' required to be set out in this notice under sections 708A(7) and (8) *Corporations Act*.

- 5 The securities referred to above are ordinary shares in a class of securities that were ASX quoted securities, within the meaning of section 708A(5) Corporations Act, at all times in the three months before the day on which the relevant securities were issued.
- 6 The securities referred to above have been trading on ASX in circumstances where trading has not been suspended for more than a total of five days during the shorter of the period during which the class of securities were quoted and the period of 12 months before the day on which the relevant securities were issued.
- 7 No exemptions under sections 111AS or 111AT Corporations Act cover the Issuer or any person as director or auditor of the Issuer at any time during the shorter of the period during which the class of securities were quoted and the period of 12 months before the day on which the relevant securities were issued.
- 8 No order under sections 340 or 341 Corporations Act covers the Issuer or any director or auditor of the Issuer at any time during the shorter of the period during which the class of securities were quoted and the period of 12 months before the day on which the relevant securities were issued.

What is VitroGro[®] ECM

- VitroGro[®] ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.
- How it works: VitroGro[®] ECM replaces the degraded matrix of a hard to heal wound. VitroGro[®] ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration ^[1].
- An optimal scaffold: One of the characteristics of hard to heal wounds is prolonged inflammation, which damages the native ECM that would normally guide the wound healing process ^[1,2,3,4]. Replacement of this damaged ECM is a beneficial strategy for treating hard to heal wounds ^[1]. VitroGro[®] ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.
- Expert health economics modelling indicates that VitroGro[®] ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care.

[1] Widgerow AD . Deconstructing the stalled wound. Wounds 2012

[2] Schultz GS. Extracellular Matrix: review of its roles in acute and chronic wounds. World Wide Wounds. 2005

[3] Moor AN. et al. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Rep Reg. 2009

[4] International consensus, Acellular matrices for treatment of wounds. Wounds Int. 2010

About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro[®] ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: www.tissuetherapies.com